Intriguingly, AR signaling, the most commonly targeted and mutated molecular signature in metastatic castration–resistant prostate cancer, was not captured by a CENPA-focused analysis, a finding that we further confirmed in tissue culture experiments. This evidence concerns the gene CENPA and prostate cancer.